Published in Lancet on April 24, 1993
Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev (2002) 17.58
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev (1996) 13.91
Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J (2003) 5.78
Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob Agents Chemother (1996) 5.36
Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol (2001) 4.09
Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa. Microbiol Mol Biol Rev (1999) 2.73
The Pseudomonas quinolone signal regulates rhl quorum sensing in Pseudomonas aeruginosa. J Bacteriol (2000) 2.62
Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol (2005) 2.59
Surface motility of serratia liquefaciens MG1. J Bacteriol (1999) 2.55
Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa. J Bacteriol (2003) 2.41
Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother (2003) 2.30
Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest (1999) 2.24
Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun (1997) 2.14
CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol (2009) 2.10
Direct detection and identification of Pseudomonas aeruginosa in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane lipoprotein genes, oprI and oprL. J Clin Microbiol (1997) 2.04
Interference with Pseudomonas quinolone signal synthesis inhibits virulence factor expression by Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (2001) 1.86
Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother (2007) 1.71
Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens. Philos Trans R Soc Lond B Biol Sci (2007) 1.70
Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis. J Clin Microbiol (2002) 1.59
Endobronchial inflammation following Pseudomonas aeruginosa infection in resistant and susceptible strains of mice. Infect Immun (1995) 1.57
Microarray analysis of global gene expression in mucoid Pseudomonas aeruginosa. J Bacteriol (2003) 1.55
Two distinct pathways supply anthranilate as a precursor of the Pseudomonas quinolone signal. J Bacteriol (2007) 1.47
Anti-Pseudomonas aeruginosa antibody detection in patients with bronchiectasis without cystic fibrosis. Thorax (2001) 1.41
Modulation of behaviour and virulence of a high alginate expressing Pseudomonas aeruginosa strain from cystic fibrosis by oral commensal bacterium Streptococcus anginosus. PLoS One (2017) 1.39
Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Cold Spring Harb Perspect Med (2013) 1.38
Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa. Infect Immun (1996) 1.38
Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia. Infect Immun (2005) 1.34
Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis. J Clin Microbiol (2010) 1.33
Virulence properties of Pseudomonas aeruginosa lacking the extreme-stress sigma factor AlgU (sigmaE). Infect Immun (1996) 1.31
Global genomic analysis of AlgU (sigma(E))-dependent promoters (sigmulon) in Pseudomonas aeruginosa and implications for inflammatory processes in cystic fibrosis. J Bacteriol (2002) 1.29
Differential immune modulatory activity of Pseudomonas aeruginosa quorum-sensing signal molecules. Infect Immun (2004) 1.25
Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother (2004) 1.23
Regulation of intestinal non-haem iron absorption. Gut (1997) 1.18
Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther (2009) 1.18
The galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung. Infect Immun (2004) 1.18
Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2004) 1.17
Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies. Infect Immun (1995) 1.15
Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm. Antimicrob Agents Chemother (1995) 1.15
N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiol (2010) 1.15
Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax (1994) 1.15
Simple method for quantifying viable bacterial numbers in sputum. J Clin Pathol (1995) 1.13
Microbial pathogenesis in cystic fibrosis: pulmonary clearance of mucoid Pseudomonas aeruginosa and inflammation in a mouse model of repeated respiratory challenge. Infect Immun (1998) 1.11
The transcriptional regulator AlgR is essential for Pseudomonas aeruginosa pathogenesis. Infect Immun (2002) 1.10
Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin Exp Immunol (2002) 1.08
Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax (1998) 1.06
Distribution of cepacian biosynthesis genes among environmental and clinical Burkholderia strains and role of cepacian exopolysaccharide in resistance to stress conditions. Appl Environ Microbiol (2009) 1.06
Clearance of Pseudomonas aeruginosa foreign-body biofilm infections through reduction of the cyclic Di-GMP level in the bacteria. Infect Immun (2013) 1.04
Quantitation of Pseudomonas aeruginosa in wound biopsy samples: from bacterial culture to rapid 'real-time' polymerase chain reaction. Crit Care (2000) 1.03
Food as a source for quorum sensing inhibitors: iberin from horseradish revealed as a quorum sensing inhibitor of Pseudomonas aeruginosa. Appl Environ Microbiol (2012) 1.01
Microarray analysis reveals induction of lipoprotein genes in mucoid Pseudomonas aeruginosa: implications for inflammation in cystic fibrosis. Infect Immun (2004) 1.00
The myeloid differentiation factor 88 is dispensable for the development of a delayed host response to Pseudomonas aeruginosa lung infection in mice. Clin Exp Immunol (2006) 0.98
Quantitative and qualitative differences in bronchoalveolar inflammatory cells in Pseudomonas aeruginosa-resistant and -susceptible mice. Clin Exp Immunol (1999) 0.97
Influence of Pseudomonas aeruginosa quorum sensing signal molecule N-(3-oxododecanoyl) homoserine lactone on mast cells. Med Microbiol Immunol (2009) 0.96
Nitrous oxide production in sputum from cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. PLoS One (2014) 0.96
Characterization of Pseudomonas aeruginosa isolated from chronically infected children with cystic fibrosis in India. BMC Microbiol (2005) 0.96
Pediatric Cystic Fibrosis Sputum Can Be Chemically Dynamic, Anoxic, and Extremely Reduced Due to Hydrogen Sulfide Formation. MBio (2015) 0.92
Pseudomonas aeruginosa AES-1 exhibits increased virulence gene expression during chronic infection of cystic fibrosis lung. PLoS One (2011) 0.91
Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax (2002) 0.90
Sub-inhibitory concentrations of some antibiotics can drive diversification of Pseudomonas aeruginosa populations in artificial sputum medium. BMC Microbiol (2013) 0.90
Tumor necrosis factor-alpha/interleukin-10 balance in normal and cystic fibrosis children. Mediators Inflamm (2001) 0.89
Secretion of nucleoside diphosphate kinase by mucoid Pseudomonas aeruginosa 8821: involvement of a carboxy-terminal motif in secretion. J Bacteriol (2000) 0.89
Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. Antimicrob Agents Chemother (2004) 0.87
Structural and functional characterization of Pseudomonas aeruginosa global regulator AmpR. J Bacteriol (2014) 0.87
Short-sighted evolution of bacterial opportunistic pathogens with an environmental origin. Front Microbiol (2014) 0.86
Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis. Biologics (2008) 0.86
Selective early production of CCL20, or macrophage inflammatory protein 3alpha, by human mast cells in response to Pseudomonas aeruginosa. Infect Immun (2003) 0.85
Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection. Mediators Inflamm (1999) 0.84
Cystic fibrosis modifier genes. J R Soc Med (2005) 0.83
BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections. Clin Exp Immunol (2003) 0.82
Faster activation of polymorphonuclear neutrophils in resistant mice during early innate response to Pseudomonas aeruginosa lung infection. Clin Exp Immunol (2004) 0.82
Nitric oxide production by polymorphonuclear leucocytes in infected cystic fibrosis sputum consumes oxygen. Clin Exp Immunol (2014) 0.80
Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin Exp Immunol (2006) 0.79
Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report. Mediators Inflamm (1999) 0.79
Renal proximal tubule function is preserved in Cftr(tm2cam) deltaF508 cystic fibrosis mice. J Physiol (2001) 0.79
Silver-coated carbon nanotubes downregulate the expression of Pseudomonas aeruginosa virulence genes: a potential mechanism for their antimicrobial effect. Int J Nanomedicine (2015) 0.78
Antibodies against chromosomal beta-lactamase. Antimicrob Agents Chemother (1994) 0.78
Surface-mediated release of a small-molecule modulator of bacterial biofilm formation: a non-bactericidal approach to inhibiting biofilm formation in Pseudomonas aeruginosa. Adv Healthc Mater (2013) 0.78
Improvement of nutrient absorption may enhance systemic oxidative stress in cystic fibrosis patients. Mediators Inflamm (2001) 0.77
Pseudomonas aeruginosa and cystic fibrosis: Antibiotic therapy and the science behind the magic. Can J Infect Dis (1997) 0.77
Effects of growth rate and nutrient limitation on virulence factor production in Burkholderia cepacia. J Bacteriol (1995) 0.77
Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros (2015) 0.76
Study of the effects of AM-1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa. Drugs (1995) 0.76
Pseudomonas aeruginosa Aggregate Formation in an Alginate Bead Model System Exhibits In Vivo-Like Characteristics. Appl Environ Microbiol (2017) 0.76
Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin Exp Immunol (2005) 0.75
New therapeutic approaches for cystic fibrosis lung disease. J R Soc Med (2002) 0.75
Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils. Hum Vaccin Immunother (2016) 0.75
Identification of Pseudomonas aeruginosa-induced genes in human mast cells using suppression subtractive hybridization: up-regulation of IL-8 and CCL4 production. Clin Exp Immunol (2005) 0.75
Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother (2015) 0.75
Bacterial Biofilm Control by Perturbation of Bacterial Signaling Processes. Int J Mol Sci (2017) 0.75
Regulation on expression of toll-like receptors on monocytes after stimulation with the 3-o-C12-HSL molecule from Pseudomonas aeruginosa. Curr Microbiol (2012) 0.75
Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet (1991) 3.37
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet (1991) 3.26
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol (1997) 3.23
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J (2000) 3.14
Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand (1983) 3.13
Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology (1999) 3.03
Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol (1996) 2.55
N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology (2001) 2.51
An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother (1986) 2.43
Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest (1999) 2.24
Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother (1991) 2.09
Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains. J Antimicrob Chemother (1990) 2.08
Occurrence of a common lipopolysaccharide antigen in standard and clinical strains of Pseudomonas aeruginosa. J Clin Microbiol (1989) 2.07
Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand (1981) 2.03
Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother (1987) 2.00
Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax (1992) 1.97
Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J Antimicrob Chemother (2004) 1.96
[Guidelines on antibiotics in the Laegeforeningens Medicinfortegnelse 2000]. Ugeskr Laeger (2001) 1.93
Cross-reactions between Legionella pneumophila (serogroup 1) and twenty-eight other bacterial species, including other members of the family Legionellaceae. Infect Immun (1983) 1.93
Epidemiology of Pseudomonas aeruginosa infection in patients treated at a cystic fibrosis centre. Acta Pathol Microbiol Scand B (1980) 1.90
Crossed immunoelectrophoretic analysis of Legionella pneumophila serogroup 1 antigens. Infect Immun (1983) 1.89
Chromosomal beta-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. J Antimicrob Chemother (2000) 1.85
Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol (2000) 1.85
Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms. Infect Immun (1990) 1.81
An antigen common to a wide range of bacteria. I. The isolation of a 'common antigen' from Pseudomonas aeruginosa. Acta Pathol Microbiol Scand B (1980) 1.75
Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun (1983) 1.68
The role of immune complexes in the pathogenesis of bacterial infections. Annu Rev Microbiol (1986) 1.67
Detection of N-acylhomoserine lactones in lung tissues of mice infected with Pseudomonas aeruginosa. Microbiology (2000) 1.66
Immunological cross-reaction between antigen Tp-4 of Treponema pallidum and an antigen common to a wide range of bacteria. Acta Pathol Microbiol Immunol Scand B (1984) 1.60
Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis. J Infect Dis (1983) 1.56
Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathol (1999) 1.54
Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun (1990) 1.51
Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol (1993) 1.51
Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis. J Clin Microbiol (1988) 1.50
Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol (1987) 1.49
Comparative immunochemistry of lipopolysaccharides from typable and polyagglutinable Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol (1988) 1.46
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros (2008) 1.46
An antigen common to a wide range of bacteria. 2. A biochemical study of a "common antigen" from Pseudomonas aeruginosa. Acta Pathol Microbiol Scand B (1980) 1.45
Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. J Urol (1994) 1.43
The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother (1987) 1.42
Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax (1992) 1.42
Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros (2009) 1.41
Role of Pseudomonas aeruginosa exoenzymes in lung infections of patients with cystic fibrosis. Infect Immun (1985) 1.41
A ten year review of colomycin. Respir Med (2000) 1.40
Pseudomonas aeruginosa mutations in lasI and rhlI quorum sensing systems result in milder chronic lung infection. Microbiology (2001) 1.39
[Guidelines for antibiotic use in the Laegeforeningens Medicinfortegnelse 2000]. Ugeskr Laeger (2001) 1.39
[Decreasing vaccination rate--increasing risk of epidemics]. Ugeskr Laeger (1996) 1.38
Pseudomonas aeruginosa exoproteases inhibit human neutrophil chemiluminescence. Infect Immun (1984) 1.37
Interaction of Pseudomonas aeruginosa alkaline protease and elastase with human polymorphonuclear leukocytes in vitro. Infect Immun (1984) 1.34
The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS (2000) 1.33
Immunogenicity of Pseudomonas aeruginosa outer membrane antigens examined by crossed immunoelectrophoresis. Infect Immun (1983) 1.33
Terminal truncations in amp C beta-lactamase from a clinical isolate of Pseudomonas aeruginosa. Eur J Biochem (1999) 1.30
[Treatment of upper respiratory tract infections?]. Ugeskr Laeger (2000) 1.29
Production of N-acyl-L-homoserine lactones by P. aeruginosa isolates from chronic lung infections associated with cystic fibrosis. FEMS Microbiol Lett (2000) 1.28
Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros (2011) 1.28
Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol (1989) 1.28
Polyagglutinability due to loss of O-antigenic determinants in Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Acta Pathol Microbiol Immunol Scand B (1985) 1.25
Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr Scand (1987) 1.24
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother (2001) 1.24
Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS (1994) 1.22
Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori. Clin Diagn Lab Immunol (1995) 1.22
Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr Pulmonol (1998) 1.22
Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol (1999) 1.22
Studies on hypersensitivity to bacterial antigens in intrinsic asthma. Allergy (1982) 1.20
Urinary tract infections in patients with spinal cord lesions: treatment and prevention. Drugs (2001) 1.19
Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different beta-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region. Antimicrob Agents Chemother (1997) 1.19
Diagnosis and treatment of cystic fibrosis. Respiration (2000) 1.19
Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS (1993) 1.19
Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS (1997) 1.19
Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect (1983) 1.18
Hypergammaglobulinemic purpura in cystic fibrosis. Acta Paediatr Scand (1978) 1.18
Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase. APMIS (2000) 1.17
Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax (2009) 1.17
Antibody response in patients with Pseudomonas aeruginosa infection to a 'common antigen' from P. aeruginosa analysed by means of quantitative immunoelectrophoretic methods. Acta Pathol Microbiol Scand C (1980) 1.17
Intrinsic asthma and bacterial histamine release. Agents Actions (1982) 1.17
Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Infect Immun (1988) 1.17
Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J (2006) 1.17
Robbins device in biofilm research. Methods Enzymol (1999) 1.15
Genome fingerprinting as a typing method used on polyagglutinable Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS (1991) 1.15
Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax (1994) 1.15
Quantitative immunoelectrophoretic analysis of Salmonella typhi antigens and of corresponding antibodies in human sera. Acta Pathol Microbiol Scand B (1980) 1.15
Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis. Acta Paediatr Scand (1982) 1.14
Sequence analysis of the Legionella micdadei groELS operon. FEMS Microbiol Lett (1991) 1.13
Antibacterial precipitins and autoantibodies in serum of patients with cystic fibrosis. Scand J Respir Dis (1975) 1.13
Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response. APMIS (1999) 1.12
Tuberculostearic acid as a diagnostic marker in tuberculous meningitis. Lancet (1983) 1.12
Intrinsic asthma and bacterial histamine release via lectin effect. Agents Actions (1983) 1.11
Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Am J Respir Crit Care Med (1995) 1.10
Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis. J Clin Microbiol (1990) 1.08
Chronic Pseudomonas aeruginosa lung infection in normal and athymic rats. APMIS (1993) 1.08
High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment. Antimicrob Agents Chemother (1992) 1.07
Elastase from polymorphonuclear leucocytes: a regulatory enzyme in immune complex disease. Clin Exp Immunol (1986) 1.07
Microbiological and immunological studies in a case of human melioidosis diagnosed in Denmark. Scand J Infect Dis (1982) 1.07
Detection of proteases of Pseudomonas aeruginosa in immune complexes isolated from sputum of cystic fibrosis patients. Acta Pathol Microbiol Immunol Scand C (1984) 1.07
Does centralized treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection? Acta Paediatr Scand (1986) 1.07
Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect Immun (1994) 1.07
Comparison of ribotyping and genome fingerprinting of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol (1996) 1.06
Comparative immunochemistry of lipopolysaccharides from Branhamella catarrhalis strains. Infect Immun (1991) 1.06
Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin. Eur J Respir Dis (1982) 1.05
Ginseng treatment enhances bacterial clearance and decreases lung pathology in athymic rats with chronic P. aeruginosa pneumonia. APMIS (1997) 1.05